ArticlePediatric nephrology (Berlin, Germany)2017
Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Predictive role of Oxford Classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.Pediatric nephrology (Berlin, Germany) · 2026Review
- Heterogeneous Renal Trajectories in Pediatric IgA Nephropathy: A Single-Center Experience Highlighting the Dynamic Nature of Early Disease.Pediatric reports · 2026Article
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- Prognosis and predictive factors in pediatric IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2026Article
- How to Cure Autoimmune GN and Podocytopathies.Journal of the American Society of Nephrology : JASN · 2026Review
- Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country.World journal of nephrology · 2025Article
- Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy.Renal failure · 2025Article
- Retrospective analysis of glucocorticoid therapy in pediatric immunoglobulin A nephropathy: Kidney outcomes and efficacy.Pediatric nephrology (Berlin, Germany) · 2025Article
- CKD progression, kidney failure, and mortality among US patients with IgA nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Recent Developments in Pediatric Nephrology.Journal of clinical medicine · 2025Article
- Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.Canadian journal of kidney health and disease · 2025Review
- Combined Therapy with Azathioprine, Prednisone, and Enalapril in Children with IgAN and IgAVN.Journal of clinical medicine · 2024Article
- MEST C Score and Treatment Response in IgA Nephropathy in a Tertiary Care Hospital: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2024Article
- Childhood-onset IgA nephropathy: is long-term recovery possible?Pediatric nephrology (Berlin, Germany) · 2024Article
- IgA nephropathy in children: before and after the start of COVID-19.Pediatric nephrology (Berlin, Germany) · 2024Article
- IgA nephropathy in children with minimal proteinuria: to biopsy or not to biopsy?Pediatric nephrology (Berlin, Germany) · 2024Article
- A lack of KDIGO guidelines for adolescents and young adults with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2024Review
- Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.Kidney international reports · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
50 authors at 20 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a need for early identification of children with immunoglobulin A nephropathy (IgAN) at risk of progression of kidney disease.
methodsData on 261 young patients [age <23 years; mean follow-up of 4.9 (range 2.5-8.1) years] enrolled in VALIGA, a study designed to validate the Oxford Classification of IgAN, were assessed. Renal biopsies were scored for the presence of mesangial hypercellularity (M1), endocapillary hypercellularity (E1), segmental glomerulosclerosis (S1), tubular atrophy/interstitial fibrosis (T1-2) (MEST score) and crescents (C1). Progression was assessed as end stage renal disease and/or a 50 % loss of estimated glomerular filtration rate (eGFR) (combined endpoint) as well as the rate of renal function decline (slope of eGFR). Cox regression and tree classification binary models were used and compared.
resultsIn this cohort of 261 subjects aged <23 years, Cox analysis validated the MEST M, S and T scores for predicting survival to the combined endpoint but failed to prove that these scores had predictive value in the sub-group of 174 children aged <18 years. The regression tree classification indicated that patients with M1 were at risk of developing higher time-averaged proteinuria (p < 0.0001) and the combined endpoint (p < 0.001). An initial proteinuria of ≥0.4 g/day/1.73 m
conclusionThis new statistical approach has identified clinical and histological risk factors associated with outcome in children and young adults with IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.